Лутикизумаб
LutikizumabМНН
Rec. INN (наименование, зарегистрированное ВОЗ)
Drugbank
DB16224
CAS
1791411-57-8
Химическое название
immunoglobulin G1-kappa, anti-[Homo sapiens IL1A (interleukin 1 alpha) and Homo sapiens IL1B (interleukin 1 beta, IL-1B, 1L1F2)], humanized monoclonal antibody, tetravalent bispecific;
gamma1 heavy chain (1-577) [humanized VH anti-IL1B (Homo sapiens IGHV3-23*04 (80.60%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -6-mer linker (120-125) -Homo sapiens VH anti-IL1A (IGHV3-30*03 (88.80%) -(IGHD)-IGHJ1*01) [8.8.15] (126-247) -Homo sapiens IGHG1*01 (CH1 (248- 345), hinge (346-360), CH2 L1.3>A (364), L1.2>A (365), (361-470), CH3 (471-575), CHS (576-577)) (248-577)], (350-327')-disulfide with kappa light chain (1'-327') [humanized V-KAPPA anti-IL1B (Homo sapiens IGKV1- 27*01 (82.10%) -IGKJ2*01) [6.3.9] (1'-106') -7-mer linker - Homo sapiens V-KAPPA anti-IL1A (IGKV1-12*01 (92.60%) -IGKJ4*01) [6.3.9] (114'-220') -Homo sapiens IGKC*01, Km3 (221'-327')]; dimer (356-356":359-359")-bisdisulfide
gamma1 heavy chain (1-577) [humanized VH anti-IL1B (Homo sapiens IGHV3-23*04 (80.60%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -6-mer linker (120-125) -Homo sapiens VH anti-IL1A (IGHV3-30*03 (88.80%) -(IGHD)-IGHJ1*01) [8.8.15] (126-247) -Homo sapiens IGHG1*01 (CH1 (248- 345), hinge (346-360), CH2 L1.3>A (364), L1.2>A (365), (361-470), CH3 (471-575), CHS (576-577)) (248-577)], (350-327')-disulfide with kappa light chain (1'-327') [humanized V-KAPPA anti-IL1B (Homo sapiens IGKV1- 27*01 (82.10%) -IGKJ2*01) [6.3.9] (1'-106') -7-mer linker - Homo sapiens V-KAPPA anti-IL1A (IGKV1-12*01 (92.60%) -IGKJ4*01) [6.3.9] (114'-220') -Homo sapiens IGKC*01, Km3 (221'-327')]; dimer (356-356":359-359")-bisdisulfide
Структура
Иностранные названия
- Lutikizumabum (латинское)
- Lutikizumab (английское)
- Lutikizumab (немецкое)
- Lutikizumab (французское)
- Lutikizumab (испанское)
Подробнее по теме
Узнайте дополнительные сведения о действующем веществе Лутикизумаб: